Nascent Biotech, Inc

Nascent Biotech, Inc.(OTCMKTS:NBIO) is a public company, formed in March 2014, to continue development of Pritumumab, a human monoclonal antibody created by a number of leading scientists who have developed various monoclonal antibodies and cytokine treatments for oncology indications. Pritumumab recognizes a unique and proprietary antigen expressed on the surface of cancer cells and is being developed to treat brain and pancreatic cancers, both unmet clinical needs. NBIO’s clinical premise is that the most effective way to treat disease is to modulate (boost or suppress) the human body’s natural ability to generate an immune response. Often referred to as “immunotherapy”, the scientific approach is based upon two discrete types of regulatory molecules, monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness in a variety of diseases. Monoclonal antibodies (mAbs) are naturally occurring proteins that bind with exquisite specificity to molecular structures on the surface of target cells. Monoclonal antibodies are, collectively, the fastest growing products in the entire pharmaceutical industry. In 2005, no mAbs were among the top 10 selling drugs in the world. By 2010, they were 5 of the top 10 selling drugs, accounting for $34.1 billion in annual sales and 45% of total sales of the top 10. By 2013, 6 of the top 10 selling drugs worldwide were mAbs accounting for $50.1 billion in sales – 66% of top-10 total sales worldwide.